CD274 and neoplasm: Recent studies, such as KEYNOTE-042, demonstrated that tissue-TMB (tTMB) can serve as a predictive biomarker for pembrolizumab monotherapy in patients with advanced/metastatic PD-L1 tumor proportion scores of ≥1% NSCLC (p<0.001), with a tTMB cut-off of ≥175 mutations/exome [47].